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INTRODUCTION
Acquired hemophilia (AH) is a rare and potentially life-th-
reatening coagulation disorder caused by spontaneous devel-
opment of antibodies to clotting factor VIII (FVIII) in non-
hemophilic children (1). AH has been described in association
with the postpartum period as well as autoimmune, derma-
tologic, infectious and oncologic diseases, and selected drugs
(2, 3). AH in non-hemophilic children is usually non-specific,
transient, and not associated with clinical bleeding, but severe
cases with catastrophic consequences have been reported (4).
In severe cases, bleeding may be prolonged due to poor clin-
ical response to FVIII replacement therapy in the continued
presence of anti-FVIII (1).
M. pneumoniae is a common cause of pneumonia especially
in young children and adults and may give rise to protean
extrapulmonary manifestations including hematologic (e.g.,
thrombocytopenia, splenomegaly, disseminated intravascular
coagulation, and hemolytic anemia), dermatologic (e.g., Ste-
vens-Johnson syndrome), gastrointestinal (e.g., vomiting,
diarrhea, and pancreatitis), renal (e.g., interstitial nephritis
and glomerulonephritis), cardiac (e.g., pericarditis, myocardi-
tis, and pericardial effusion) and central nervous system (e.g.
meningitis, transverse myelitis, polyradiculopathy, cerebel-
lar ataxia, and sensorineural hearing loss) conditions (5). The
underlying causes of M. pneumoniae-associated extrapulmonary
manifestations are unknown. While transient acquired fac-
tor II deficiency has been described in association with M.
pneumoniae, there are no reports of AH and anti-FVIII with
M. pneumoniae (6). In this report, we describe a 33-month-
old girl with serologically and polymerase chain reaction
(PCR)-confirmed infection with M. pneumonia and AH, who
was successfully treated with prednisone and intravenous
immunoglobulin (IVIG) therapy.
CASE REPORT
A previously healthy 33-month-old girl presented to an out-
lying hospital with a 10-day history of high fever, sore throat,
and non-productive cough. Because of worsening lower re-
spiratory tract symptoms including severe cough, acute onset
hematochezia, and numerous ecchymoses, she was transferred
to our facility for further treatment. The girl’s parents report-
ed no prior illness or history of bleeding problems in the child,
siblings, or other family members. At the time of admission
following transfer, she appeared febrile with diminished breath
sounds and rales over the left lower lung field. Multiple ecchy-
motic skin lesions were visible over the upper and lower ex-
tremities. No evidence of hemarthroses or soft tissue hematomas
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Transient Acquired Hemophilia Associated with Mycoplasma
Pneumoniae Pneumonia
Acquired hemophilia is a rare disorder caused by autoantibodies to factor VIII (FVIII)
(also referred to as factor VIII inhibitors or anti-FVIII) and may be associated with
pregnancy, underlying malignancy, or autoimmune disorders. A 33-month-old girl
who presented with hematochezia and ecchymotic skin lesions was diagnosed
with Mycoplasma pneumoniae pneumonia by serology and polymerase chain reac-
tion. Hematologic studies showed a prolonged activated partial thromboplastin time
(aPTT), partially corrected mixing test for aPTT, reduced levels of FVIII, and the
presence of antibodies against FVIII. She was treated conservatively with pred-
nisone and intravenous immunoglobulin (IVIG) without FVIII transfusion and recov-
ered without sequelae. This report provides the first description of acquired hemophil-
ia due to anti-FVIII in association with M. pneumoniae in Korea. We discuss this
case in the context of the current literature on acquired hemophilia in children.
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was found. No hepatosplenomegaly or sensorimotor deficits
were observed and her cardiac examination was unremarkable.
The initial laboratory studies showed normal red and white
blood cell counts, liver and renal function studies, urinalysis
and Widal test, and anti-streptolysin O titer. Fecal occult blood
testing was positive, but there was no evidence of stool leuko-
cytes. The latex agglutination test for rotavirus was negative.
Her C-reactive protein level was elevated at 8.3 mg/L (refer-
ence range, <5 mg/L). On the day of admission to our hos-
pital, her IgM antibody titer to M. pneumoniae was 1:1,280
and, on her 4th hospital day, an oropharyngeal swab was col-
lected and tested positive for M. pneumoniae by PCR (Fig. 1).
Coagulation studies revealed a normal prothrombin time
(PT) of 12.7 sec (reference range, 11.7 to 13.7 sec), and a
prolonged activated partial thromboplastin time (aPTT) of
94.0 sec (reference range, 29.8 to 41.8 sec). Plasma mixing
studies with normal control failed to correct the aPTT (77.3
sec) and raised our suspicion regarding the presence of an
inhibitor. The patient’s bleeding time was normal, FVIII
activity was 3% (reference range: 60 to 140%, STA Com-
pact, Diagnostica Stago, France), factor IX activity was 61%
(reference range, 60 to 140%), von Willebrand factor anti-
gen was 146.2% (reference range, >50%), ristocetin cofac-
tor activity was 110.1% (reference range, 45 to 160%), and
FVIII inhibitor was 2.5 Bethesda Units (BU)/mL (reference
range, <0.01 BU/mL), confirming the presence of anti-FVIII.
Additional tests showed no evidence of disseminated intravas-
cular coagulopathy, and her fibrinogen, fibrin degradation
products, and anti-thrombin 3 levels were normal. Tests of
anti-nuclear, anti-phospholipid, lupus anticoagulant, and
anti-smooth muscle cell antibodies were all negative. On
admission, her chest radiograph showed an area of ill-defined
consolidation in the left lower lobe with blunting of left cos-
tophrenic angle (Fig. 2). Based on these clinical and labora-
tory findings, we established the diagnosis of AH.
Because of her stable condition on admission and the absence
of complications such as intracranial and intramuscular he-
matomas, she was treated with daily oral prednisone (2 mg/
kg/day) and a single dose of IVIG (2 g/kg) without FVIII con-
centrate. For the treatment of her underlying Mycoplasma-asso-
ciated pneumonia, she received ceftriaxone (50 mg/kg/day)
given twice daily for 7 days and azithromycin (10 mg/kg/
day) given once daily for 3 days. The titer of FVIII inhibitor
rapidly declined without additional immunosuppressive ther-
apy. Total disappearance of autoantibodies to FVIII was achiev-
ed four weeks after admission (Fig. 3).
DISCUSSION
AH is the most common acquired clotting factor disorder
and may involve a deficiency of factors VII, VIII, or IX (7). AH
has been observed in non-hemophilic patients with a frequen-
cy of 1 to 5 cases per million persons and 50% of cases occur
in healthy persons with no underlying medical condition (8).
It is notable that AH is typically a disease of adults with most
cases reported in patients aged 50 yr and older and sometimes
in younger women of child-bearing age who experience post-
partum bleeding. Cases of AH due to anti-FVIII have only
rarely been reported in the literature and AH has not been
described in the context of M. pneumoniae infections among
Asian children (9).
Fig. 1. Detection of Mycoplasma pneumoniae DNA amplification
in a patient throat swab specimen by polymerase chain reaction.
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Fig. 2. Radiologic finding on admission. Chest radiograph shows
consolidation in left lower lung field and blunting of the costophrenic
angle.
Fig. 3. The changes of aPTT, FVIII, factor VIII inhibitor during treat-
ment. aPTT, activated partial thromboplastin time; F VIII, factor VIII;
F VIII-I, factor VIII inhibitor; IVIG, intravenous immunoglobulin; AMA,
anti-mycoplasma antibody.
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Clinically, the bleeding pattern in AH patients is charac-
terized by hematoma formation in fascial planes or mucosal
bleeding in contrast to congenital hemophilia in whom he-
marthroses are more common. Hemorrhagic manifestations
may be severe including upper and lower gastrointestinal bleed-
ing that may initially present in previously healthy individ-
uals or following surgical procedures. AH should be suspect-
ed in patients who have no personal or family history of bleed-
ing disorders and develop a hemorrhagic diathesis accompa-
nied by a prolonged aPTT. The aPTT is a reliable screening
test to detect anti-FVIII as it will be prolonged when FVIII
activity falls below 45% of the mean normal level. In AH,
mixing studies using patient plasma and normal plasma will
not normalize the aPTT and the FVIII activity, whereas in
cases with clotting factor deficiency, the prolonged aPTT
will be corrected following the addition of normal plasma (10).
Thus, mixing studies provide a critical tool to distinguish
between the presence of a coagulation factor deficiency and a
circulating anti-FVIII. Antibodies to FVIII may be quantified
by the Bethesda assay that allows quantitation of the inhibitor
strength (11). In our patient, we confirmed the diagnosis of
AH by the presence of multiple ecchymotic lesions, a pro-
longed aPTT, normal PT, low FVIII activity, and the pres-
ence of FVIII inhibitor.
Up to 36% of patients who do not receive immunosuppres-
sants experience a spontaneous disappearance of their autoan-
tibodies, but the predictors of spontaneous resolution are not
well-known. Thus, prompt therapy is needed when AH is
confirmed (12, 13). In patients with AH, the primary goal
is to achieve effective control of bleeding closely followed by
elimination of the anti-FVIII using one or more factor con-
centrates or immunosuppressive agents. The choice of agent
for hemostasis depends on the severity of bleeding and the
titer of anti-FVIII. Desmopressin, human FVIII (hFVIII) or
porcine FVIII (pFVIII) may raise FVIII activity. If the anti-
FVIII titer is high (>5 BU) or bleeding continues despite
the use of hFVIII or pFVIII infusions, other FVIII bypass-
ing agents, such as activated prothrombin complex concen-
trates, recombinant factor VIIa or recombinant human acti-
vated factor VII may be used (13). In patients who are resis-
tant to treatment with factor concentrates or FVIII bypass-
ing agents, immunosuppressive therapy may be considered
(13). Immunosuppressants may be called for in cases for whom
bleeding is life-threatening, where factor concentrates may
not be readily available, or when resolution does not occur
with factor concentrates.
At present, there are neither gold standard treatments nor
standardized therapeutic guidelines. However, for several years,
corticosteroids and cyclophosphamide have been the mainstay
of treatment in AH. The use of prednisone in AH typically
results in the disappearance of anti-FVIII within 3 to 6 weeks
in approximately 50% of cases. The addition of oral cyclophos-
phamide may double the response rate in AH patients who
are resistant to steroids (10). However, other combination ther-
apies appear to be effective in eliminating anti-FVIII, includ-
ing prednisone plus azathioprine or prednisone plus cyclophos-
phamide and vincristine. In patients who do not respond to
cyclophosphamide, azathioprine, vincristine, and cyclosporin
A may be considered either alone or in combination with pred-
nisone as a salvage therapy (13). In addition to the use of im-
munosuppressive agents, the use of high-dose IVIG, plasma-
pheresis, and plasma exchange has also proven effective for some
patients with AH (14). Our patient was treated successfully
with a combination of prednisone and IVIG (15), which led
to a complete resolution of clinical and laboratory abnormal-
ities after 4 weeks of treatment. The prognosis of patients with
AH is quite variable. In some cases, remission may occur with-
in a few months but, in others, anti-FVIII may persist for years.
Although the etiology of this disorder remains unclear,
about 40-50% of AH cases are associated with autoimmune
diseases such as rheumatoid arthritis or systemic lupus ery-
thematosus, graft-versus-host disease after allogenic bone
marrow transplantation, the postpartum period, underlying
malignancies, or drug administration (e.g., penicillin, sulfon-
amides, chloramphenicol, and others) (8). AH has also been
reported in association with BCG and influenza vaccination,
but the causal pathway in these cases remains unclear (16).
Sixteen different Mycoplasma species have been found to colo-
nize the upper respiratory and genitourinary tract in humans
and, of these, M. pneumoniae is the most important pathogen
in children (17). Despite several reports of the extrapulmonary
manifestations associated with M. pneumoniae infection, the
mechanism by which this injury occurs has not yet been estab-
lished. Recent data suggest that several autoantibodies may
be produced during infection with Mycoplasma including cold
agglutinins and autoantibodies against pulmonary and cen-
tral nervous system tissue as well as cardiolipin and smooth
muscle tissue. In some cases, it is thought that this autoim-
mune response appears to result from molecular mimicry
due to homology between mammalian structural proteins
and the mycoplasmal P1 adhesin (18). These autoantibodies
may inhibit binding of FVIII to von Willebrand factor or
phospholipid (preventing the association of FVIII with fac-
tor IXa), block the binding of factor Xa to FVIII, or interfere
with the formation of the FVIIIa-factor IXa-phospholipid
(tenase) complex. Additionally, autoantibodies have also been
described to catalyze the hydrolysis of FVIII (19).
While the pathogenic mechanisms of AH remain unclear,
recent evidence from experimental studies of Mycoplasma
suggests that a clonal expansion of B lymphocytes is impor-
tant (20, 21). It is well known that bacterial lipopeptides
(sometimes called lipid-associated membrane proteins) such
as the Macrophage Activating Lipoprotein 2 (MALP2) found
in Mycoplasma species may stimulate B lymphocytes via a path-
way involving Toll-like receptor 2 (TLR2) activation of nucle-
ar factor-kappaB (NF-kB). If TLR2 and other TLRs (e.g., TLR1
and TLR6) prove to be important in the causal pathway to
AH and other autoimmune disorders, agents targeting one or
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more TLRs may provide a new and effective class of immuno-
modulating agents.
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